RFA-DA-24-018: Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2023.
National Institutes of Health offered grants of up to $295,924 to small businesses. Applications closed on November 10, 2023.
From the official notice on Grants.gov, last changed May 23, 2023. Checked November 7, 2026.
- Award ceiling$295,924
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR43 / R44
- Clinical trialsOptional
- Funded byNIDA
- Median yearly award$295,768
- Typical project length2 years
- R43, Small Business Innovation Research (SBIR) Phase I. A small business tests the feasibility of a technology or product. Other open R43 notices.
- R44, Small Business Innovation Research (SBIR) Phase II. Full research and development of an SBIR project after Phase I (or both phases at once, called Fast Track). Other open R44 notices.
Projects funded under RFA-DA-24-018 were run by National Institute on Drug Abuse (NIDA, 5 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-DA-24-018 in the NIH Guide.
Key dates
| Posted | May 23, 2023 |
|---|---|
| Deadline | November 10, 2023 |
| Archived by Grants.gov | December 16, 2023 |
Who can apply
This opportunity was open to small businesses.
- Small businesses
Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See full Notice of Funding Opportunity for additional details on eligibility.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $295,768; it allows up to $295,924 per award.
- Most of the program's money (70% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The FOA intends to spur the development of cost-effective technologies that may reduce or even eliminate disparities in SUD treatment. Disparities due to geographical access or rural/urban divide, due to treatment cost, or due to stigma will be specifically targeted. The intention is to bring to the treatment to the patient, not the patient to the treatment.
Funded under RFA-DA-24-018 so far
NIH funded 5 projects under RFA-DA-24-018 in fiscal 2024 to 2026, at 5 institutions. The median yearly award was $295,768.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings | Boulder Care, Inc. | 2026 | $826,352 |
| Advancing Access to Opiate Care and Treatment through a Novel Liquid Methadone Dispensing Device and SMART Container | Sano Healthcare Consultants, LLC | 2024 | $319,000 |
| Wearable Continuous Drug Monitoring Device for Personal Medications in Opioid Use Disorders (CDM-MOUD) | Labsys, LLC | 2024 | $294,474 |
| Field-Deployable, low-Cost Point-of-Need urine test strips for mobile quantification of SUD medication drugs and their metabolites | Vitan-Biotech, LLC | 2024 | $293,468 |
| Remote and Non-Invasive Opioid Use Screening to Lower Barriers to Substance Use Disorder Diagnosis and Treatment | Tenvos Inc. | 2024 | $293,170 |
Who has won Drug Use and Addiction Research Programs grants before
From fiscal 2021 to 2025, Drug Use and Addiction Research Programs (93.279) awarded $7.3 billion across 5,071 grant awards, an average of $1.4 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Yale Univ | Connecticut | 150 | $305 million |
| The Johns Hopkins University | Maryland | 156 | $262 million |
| University of California, San Diego | California | 120 | $242 million |
| University of Pittsburgh - of the Commonwealth System of Higher Education | Pennsylvania | 100 | $182 million |
| New York University | New York | 62 | $173 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-DA-24-018 still open?
No. It closed on November 10, 2023.
Who can apply for Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional)?
National Institutes of Health accepted applications from small businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Field-Deployable, Low-Cost Point-of-Need Approaches and Technologies to Lower the Barriers to Substance Use Disorders (SUD) Diagnosis and Treatment (R43/R44 Clinical Trial Optional)?
Closed November 10, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $295,924 each.
Who has been funded under RFA-DA-24-018?
NIH RePORTER lists 5 projects funded under RFA-DA-24-018 in fiscal 2024 to 2026, at 5 institutions. The most were at Boulder Care, Inc., Sano Healthcare Consultants, LLC, Labsys, LLC.
Who has won Drug Use and Addiction Research Programs grants before?
The largest recipients over five fiscal years were Yale Univ, The Johns Hopkins University, University of California, San Diego. The program made 5,071 awards worth $7.3 billion in that time.
Similar open grants
- Small Business Transition Grant for New Entrepreneurs (Parent R43/R44 Clinical Trial Optional)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)